BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38291522)

  • 21. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.
    Fatourechi V; Hay ID
    Semin Nucl Med; 2000 Apr; 30(2):107-14. PubMed ID: 10787191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma.
    Lee HJ; Rha SY; Jo YS; Kim SM; Ku BJ; Shong M; Kim YK; Ro HK
    Am J Clin Oncol; 2007 Feb; 30(1):63-8. PubMed ID: 17278897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
    Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
    J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
    Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
    Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
    Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.
    Saghari M; Gholamrezanezhad A; Mirpour S; Eftekhari M; Takavar A; Fard-Esfahani A; Fallahi B; Beiki D
    Nucl Med Commun; 2006 Jul; 27(7):567-72. PubMed ID: 16794517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
    Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
    Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
    Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is postablation whole-body
    Liu B; Chen Y; Jiang L; He Y; Huang R; Kuang A
    Clin Endocrinol (Oxf); 2017 Jan; 86(1):134-140. PubMed ID: 27434740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of fractionated doses of iodine-131 for ablation of thyroid remnants.
    Wang SJ; Liu TJ
    Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jul; 65(7):336-40. PubMed ID: 12365652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
    Kim HK; Yoon JH; Cho JS; Kwon SY; Yoo SW; Kang HC
    Korean J Intern Med; 2020 Sep; 35(5):1164-1172. PubMed ID: 31352718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
    Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
    Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful thyroid tissue ablation as defined by a negative whole-body scan or an undetectable thyroglobulin: a comparative study.
    Karam M; Feustel PJ; Postal ES; Cheema A; Goldfarb CR
    Nucl Med Commun; 2005 Apr; 26(4):331-6. PubMed ID: 15753792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.